Latest From Endomagnetics Ltd.
Endomag is making plans to shake up the US breast cancer market with its Sentimag and Magtrace combination breast cancer system, which recently earned US FDA approval. The company recently raised $10m to scale its commercial operations.
US FDA's new Oncology Center for Excellence brought in key experts to help review and approve Endomag's new Magtrace and Sentimag System combination product to help surgeons trace and remove breast tumors. The case highlights how disease-specific centers could change the way the agency reviews products, and it also spotlights the agency's recent efforts to improve combination product reviews. Check out our Q&A with FDA's Binita Asher.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.
- Diagnostic Imaging Equipment & Supplies
- Surgical Equipment & Devices
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Endomagnetics Ltd.
- Senior Management
Eric Mayes, PhD, CEO
Andrew Shawcross, PhD, COO
Rob Hincks, Dir., Fin.
Quentin Harmer, PhD, CTO
- Contact Info
Phone: 1223 652540
Jeffrey's Bldg. St. John's Innovation Pk
Cambridge, CB4 0WS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.